Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Erica Mayer, MD, MPH
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California, San Francisco
San Francisco, California, United States
- Indiana University Health Hospital
Indianapolis, Indiana, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Mgh/north Shore Cancer Center
Danvers, Massachusetts, United States
- Df/dwcc at Milford Regional Cancer Center
Milford, Massachusetts, United States
- South Shore Hospital
Weymouth, Massachusetts, United States
- Dana-Farber/new Hampshire Oncology-Hematology
Londonderry, New Hampshire, United States
- University of Pennsylvania-Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2014
- Primary completion
- 31 May 2018
- Completion
- 27 Dec 2024
- Last update posted
- 29 Apr 2025
- Registered enrollment
- 162
- Registry id
- NCT02040857
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.